{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:49:34Z","timestamp":1791748174859,"version":"4.3.4"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82501058"],"award-info":[{"award-number":["82501058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019035","name":"Hubei Province Science and Technology Program","doi-asserted-by":"publisher","award":["2025AFB228"],"award-info":[{"award-number":["2025AFB228"]}],"id":[{"id":"10.13039\/501100019035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedic Translation"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jot.2026.101235","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:25:26Z","timestamp":1791667526000},"page":"101235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders"],"prefix":"10.1016","volume":"61","author":[{"given":"Yimei","family":"Que","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xienilai","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhou","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zedong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changtian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xugui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jot.2026.101235_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.jot.2026.101235_bib2","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3390\/jcm12072506","article-title":"Chondrosarcoma: a clinical review","volume":"12","author":"Gazendam","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jot.2026.101235_bib3","article-title":"Research progress of bone metastases: from disease recognition to clinical practice","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib5","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.3390\/jcm10153289","article-title":"Prevalence trend and disparities in rheumatoid arthritis among us adults, 2005-2018","volume":"10","author":"Xu","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jot.2026.101235_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-018-0662-5","article-title":"From a patient advocate's perspective: does cancer immunotherapy represent a paradigm shift","volume":"20","author":"Madden","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jot.2026.101235_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12026-021-09236-x","article-title":"Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology","volume":"69","author":"Yoo","year":"2021","journal-title":"Immunol Res"},{"key":"10.1016\/j.jot.2026.101235_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jot.2026.101235_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jot.2026.101235_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR-T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"10.1016\/j.jot.2026.101235_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR-T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR-T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the eliana trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"Kte-x19 for relapsed or refractory adult b-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre zuma-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jot.2026.101235_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jot.2026.101235_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a b-cell maturation antigen-directed chimeric antigen receptor t-cell therapy in patients with relapsed or refractory multiple myeloma (cartitude-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jot.2026.101235_bib17","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in cartitude-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib18","doi-asserted-by":"crossref","first-page":"e926","DOI":"10.5435\/JAAOS-D-25-00392","article-title":"Influence of chimeric antigen receptor t-cell therapy on fracture risk of patients with multiple myeloma","volume":"34","author":"Huynh","year":"2026","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.jot.2026.101235_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00774-024-01539-x","article-title":"Crosstalk between bone and the immune system","volume":"42","author":"Okamoto","year":"2024","journal-title":"J Bone Miner Metabol"},{"key":"10.1016\/j.jot.2026.101235_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108179","article-title":"Crosstalk between immune cells and bone cells or chondrocytes","volume":"101","author":"Deng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jot.2026.101235_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019489","article-title":"Editorial: the bone\/bone marrow microenvironment: a hub for immune regulation of the tumor cells fate","volume":"13","author":"Horas","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s11864-024-01256-7","article-title":"Immunotherapy in the fight against bone metastases: a review of recent developments and challenges","volume":"25","author":"Peng","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/BOR.0000000000000923","article-title":"Inflammation in osteoarthritis: the latest progress and ongoing challenges","volume":"35","author":"Knights","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jot.2026.101235_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jot.2026.101235_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR-T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jot.2026.101235_bib26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/ITT.S291767","article-title":"Fibroblast activation protein (fap)-targeted CAR-T cells: launching an attack on tumor stroma","volume":"10","author":"Bughda","year":"2021","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.jot.2026.101235_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR-T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jot.2026.101235_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.jot.2026.101235_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib31","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR-T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the erbb signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jot.2026.101235_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00003086-200101000-00010","article-title":"Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma","author":"Morris","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.jot.2026.101235_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00094","article-title":"Pepn1924, a phase ii study of trastuzumab deruxtecan in patients with recurrent human epidermal growth factor receptor 2+ osteosarcoma: a children's oncology group pediatric early-phase clinical trial network study","author":"Reed","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.jot.2026.101235_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing erbb2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.jot.2026.101235_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jot.2026.101235_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7anti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib39","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00262-026-04319-w","article-title":"Unaltered NKG2D-CAR T cell function under hypoxia in osteosarcoma in vitro","volume":"75","author":"Hidalgo","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jot.2026.101235_bib41","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","article-title":"B7-H3 is widely expressed in soft tissue sarcomas","volume":"24","author":"Lynch","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib42","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR-T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691741","article-title":"A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3 CAR-T cells","volume":"12","author":"Talbot","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib44","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1038\/s41467-023-39097-x","article-title":"Alpl-1 is a target for chimeric antigen receptor therapy in osteosarcoma","volume":"14","author":"Mensali","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jot.2026.101235_bib45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13046-019-1147-6","article-title":"Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jot.2026.101235_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919855491","article-title":"Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma","volume":"11","author":"Riccardo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12916-026-04729-8","article-title":"Oncostatin-m ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma","volume":"24","author":"Feinberg","year":"2026","journal-title":"BMC Med"},{"key":"10.1016\/j.jot.2026.101235_bib49","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/2767-9764.CRC-25-0086","article-title":"Preclinical evaluation of folate receptor-\u03b1 chimeric antigen receptor T cells exhibits highly efficient antitumor activity against osteosarcoma","volume":"5","author":"Choe","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jot.2026.101235_bib50","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-24-2335","article-title":"LRRC15-CAR-T cells for the treatment of osteosarcoma","volume":"32","author":"O'Reilly","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70140","article-title":"Enhancement of anti-sarcoma immunity by nk cells engineered with mRNA for expression of a EphA2-targeted CAR","volume":"15","author":"Lam","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jot.2026.101235_bib52","article-title":"Non-viral TcBuster transposon engineering of CD70-CAR natural killer cells for the treatment of osteosarcoma","volume":"34","author":"Robbins","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib54","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jot.2026.101235_bib55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/pharmaceutics16020251","article-title":"Immunotherapy innovations in the fight against osteosarcoma: emerging strategies and promising progress","volume":"16","author":"Cheng","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jot.2026.101235_bib56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jot.2026.101235_bib57","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: esmo-euracan-genturis-ern paedcan clinical practice guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib58","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase i study of the mutant idh1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11060-020-03464-1","article-title":"Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes","volume":"147","author":"Lu","year":"2020","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.939166","article-title":"Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: a potential target for antibody-based immunotherapy","volume":"12","author":"Nota","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/iep.12189","article-title":"Functional roles of cspg4\/ng2 in chondrosarcoma","volume":"97","author":"Jamil","year":"2016","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.jot.2026.101235_bib63","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jnci\/djq343","article-title":"Cspg4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer","volume":"102","author":"Wang","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jot.2026.101235_bib64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2013.10.093","article-title":"High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer","volume":"441","author":"Hsu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jot.2026.101235_bib65","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/cancers13061202","article-title":"Current status of management and outcome for patients with ewing sarcoma","volume":"13","author":"Hesla","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jot.2026.101235_bib66","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pbc.25042","article-title":"The value of high-dose chemotherapy in patients with first relapsed ewing sarcoma","volume":"61","author":"Rasper","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib67","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized ewing sarcoma: a report from the children's oncology group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib68","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/jcm12062326","article-title":"CAR-T cell therapy in children with solid tumors","volume":"12","author":"Kulczycka","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jot.2026.101235_bib69","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806 CAR-T cells selectively target a tumor-restricted egfr epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jot.2026.101235_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jot.2026.101235_bib71","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/ijc.31405","article-title":"EphA2 receptor is a key player in the metastatic onset of ewing sarcoma","volume":"143","author":"Garcia-Moncl\u00fas","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","article-title":"Chimeric antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours","volume":"28","author":"Hsu","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jot.2026.101235_bib73","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory ewing sarcoma family of tumors: results of a phase ii sarcoma alliance for research through collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib74","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.2011.37.2359","article-title":"Phase ii study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors","volume":"30","author":"Tap","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib75","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-12-0061","article-title":"Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory ewing's sarcoma family tumors","volume":"18","author":"Naing","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(13)70049-4","article-title":"Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial","volume":"14","author":"Schwartz","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CCO.0000000000001048","article-title":"Emerging therapies in ewing sarcoma","volume":"36","author":"Strauss","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jot.2026.101235_bib79","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jot.2026.101235_bib80","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib81","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jot.2026.101235_bib82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jot.2026.101235_bib83","first-page":"10248","article-title":"Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: a large population-based study","volume":"13","author":"Yao","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jot.2026.101235_bib84","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of survival in patients with bone metastasis of lung cancer","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.jot.2026.101235_bib85","article-title":"Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib86","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jot.2026.101235_bib87","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-04-1842","article-title":"Prostate stem cell antigen is overexpressed in prostate cancer metastases","volume":"11","author":"Lam","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jot.2026.101235_bib88","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA CAR-T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jot.2026.101235_bib89","article-title":"GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells","volume":"9","author":"Seitz","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jot.2026.101235_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib91","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1172\/JCI97454","article-title":"Redirection to the bone marrow improves T cell persistence and antitumor functions","volume":"128","author":"Khan","year":"2018","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jot.2026.101235_bib92","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"10.1016\/j.jot.2026.101235_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110427","article-title":"Serpinh1 modulates apoptosis by inhibiting p62 ubiquitination degradation to promote bone metastasis of prostate cancer","volume":"27","author":"Tang","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jot.2026.101235_bib94","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3390\/cancers13040810","article-title":"Modulation of the vascular-immune environment in metastatic cancer","volume":"13","author":"He","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jot.2026.101235_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1019864","article-title":"Contribution of immune cells to bone metastasis pathogenesis","volume":"13","author":"He","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jot.2026.101235_bib96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbo.2016.03.004","article-title":"The role of tumour-associated macrophages in bone metastasis","volume":"5","author":"Sousa","year":"2016","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.jot.2026.101235_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jot.2026.101235_bib99","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jot.2026.101235_bib100","article-title":"Managing inadequate response to initial anti-tnf therapy in rheumatoid arthritis: optimising treatment outcomes","volume":"14","author":"Taylor","year":"2022","journal-title":"Ther Adv Musculoskel"},{"key":"10.1016\/j.jot.2026.101235_bib101","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13075-025-03672-y","article-title":"Stepwise dose reduction and discontinuation of bdmard in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers","volume":"27","author":"Nozaki","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jot.2026.101235_bib102","article-title":"Polymorphisms and pharmacogenomics for the clinical efficacy of methotrexate in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"7","author":"Qiu","year":"2017","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.jot.2026.101235_bib103","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jot.2026.101235_bib104","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jot.2026.101235_bib105","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3389\/fimmu.2020.01608","article-title":"The future of regulatory T cell therapy: promises and challenges of implementing CAR technology","volume":"11","author":"Mohseni","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib106","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive b cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jot.2026.101235_bib107","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall'Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jot.2026.101235_bib108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8(+) T cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4(+) T cells in an antigen-specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib109","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jot.2026.101235_bib110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.actbio.2019.03.010","article-title":"Intra-articular targeting of nanomaterials for the treatment of osteoarthritis","volume":"93","author":"Brown","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1016\/j.jot.2026.101235_bib111","article-title":"Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management","volume":"19","author":"Wen","year":"2023","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.jot.2026.101235_bib112","doi-asserted-by":"crossref","first-page":"E3432","DOI":"10.1073\/pnas.1408780111","article-title":"Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions","volume":"111","author":"Lu","year":"2014","journal-title":"P Natl Acad Sci Usa"},{"key":"10.1016\/j.jot.2026.101235_bib113","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.12172","article-title":"Treg functional stability and its responsiveness to the microenvironment","volume":"259","author":"Barbi","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jot.2026.101235_bib114","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jot.2026.101235_bib115","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1038\/s41467-024-53996-7","article-title":"Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jot.2026.101235_bib116","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","article-title":"Phase I trial of autologous RNA-electroporated CMET-directed CAR-T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jot.2026.101235_bib117","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1007\/s10067-026-08101-2","article-title":"Chimeric antigen receptor macrophage (CAR-M) immunotherapy in autoimmune inflammatory rheumatic diseases","volume":"45","author":"Chikanza","year":"2026","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jot.2026.101235_bib118","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/pgs-2019-0186","article-title":"Mthfr, tyms and slco1b1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis","volume":"21","author":"Sundbaum","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jot.2026.101235_bib119","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR-T cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jot.2026.101235_bib120","first-page":"e83","article-title":"CD19-targeting CAR-T cell therapy in patients with diffuse systemic sclerosis: a case series. The Lancet","volume":"7","author":"Auth","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.jot.2026.101235_bib121","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jot.2026.101235_bib122","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jot.2026.101235_bib123","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41584-025-01223-y","article-title":"The role of the immune system in osteoarthritis: mechanisms, challenges and future directions","volume":"21","author":"Moulin","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jot.2026.101235_bib124","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrrheum.2016.65","article-title":"Ageing and the pathogenesis of osteoarthritis","volume":"12","author":"Loeser","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jot.2026.101235_bib125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-022-02859-x","article-title":"Senescence in osteoarthritis: from mechanism to potential treatment","volume":"24","author":"Liu","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jot.2026.101235_bib126","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nm.4324","article-title":"Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment","volume":"23","author":"Jeon","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jot.2026.101235_bib127","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.devcel.2014.11.012","article-title":"An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA","volume":"31","author":"Demaria","year":"2014","journal-title":"Dev Cell"},{"key":"10.1016\/j.jot.2026.101235_bib128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","article-title":"The epidemiology of osteosarcoma","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.jot.2026.101235_bib129","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR t-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jot.2026.101235_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101566","article-title":"Allogeneic \u201coff-the-shelf\u201d CAR-T cells: challenges and advances","volume":"37","author":"Chen","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jot.2026.101235_bib131","article-title":"Surface expression of the immunotherapeutic target g(d2) in osteosarcoma depends on cell confluency","volume":"4","author":"Wiebel","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.jot.2026.101235_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jot.2026.101235_bib133","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jcyt.2021.12.010","article-title":"CAR-T targets and microenvironmental barriers of osteosarcoma","volume":"24","author":"Zhu","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jot.2026.101235_bib134","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","article-title":"Synnotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jot.2026.101235_bib135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152477","article-title":"Tandem CAR-T cells targeting HER2 and il13r\u03b12 mitigate tumor antigen escape","volume":"131","author":"Hegde","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jot.2026.101235_bib136","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.jot.2026.101235_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD-1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory non-hodgkin's lymphoma: a first-in-human phase i study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jot.2026.101235_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106329","article-title":"Locoregional delivery of CAR-T cells in the clinic","volume":"182","author":"Sagnella","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jot.2026.101235_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.886305","article-title":"The osteoclast traces the route to bone tumors and metastases","volume":"10","author":"Russo","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jot.2026.101235_bib140","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"P Natl Acad Sci Usa"},{"key":"10.1016\/j.jot.2026.101235_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006680","article-title":"Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody","volume":"11","author":"Park","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jot.2026.101235_bib142","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR-T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jot.2026.101235_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1865742","article-title":"Reprogramming adoptive cell therapy for osteosarcoma: engineering, vaccination, and tumor microenvironment remodeling","volume":"17","author":"Zuo","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.jot.2026.101235_bib144","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jot.2026.101235_bib145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tegfr safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jot.2026.101235_bib146","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with uniCAR-T-CD123 in relapsed\/refractory aml","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jot.2026.101235_bib147","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Orthopaedic Translation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214031X26001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214031X26001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:41:37Z","timestamp":1791747697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214031X26001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":147,"alternative-id":["S2214031X26001944"],"URL":"https:\/\/doi.org\/10.1016\/j.jot.2026.101235","relation":{},"ISSN":["2214-031X"],"issn-type":[{"value":"2214-031X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedic Translation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jot.2026.101235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Speaking Orthopaedic Society.","name":"copyright","label":"Copyright"}],"article-number":"101235"}}